At the AACR special session “Expanding and Translating Cancer Synthetic Vulnerabilities,” Faith C. Fowler et al. reported that continuous treatment of MSI-H cell lines with HRO761 and two novel WRN inhibitors led to the identification of multiple point mutations within the WRN helicase domain. These mutations directly blocked inhibitor binding and drove resistance mechanisms, highlighting the urgent need to develop next-generation WRN inhibitors capable of overcoming resistance, along with corresponding resistant cell models. To address this, Kyinno Biotechnology has independently established the WRN-MutCell platform, leveraging CRISPR/Cas9 technology to precisely introduce multiple resistance mutations at the endogenous WRN gene locus. This platform provides robust support for the structural optimization and functional evaluation of next-generation WRN inhibitors.
The Werner syndrome protein (WRN) belongs to the RecQ family of DNA helicases and plays key roles in replication fork restart, genome stability maintenance, and telomere protection. In MSI-H tumors, defects in mismatch repair lead to the accumulation of DNA secondary structures, creating a “synthetic lethal” dependency on WRN helicase activity. Inhibition of WRN selectively induces cell death in MSI-H cells.
Biological Functions of WRN
- Replication fork maintenance: In BRCA2-deficient cells, WRN promotes replication fork restart through its ATPase and helicase activities and restricts MRE11-mediated fork degradation, thereby preserving genome integrity.
- Helicase core structure: The WRN helicase core contains a winged-helix (WH) domain and an ATP-binding pocket. Residue I852 is located within a critical alpha-helical region. The I852F mutation alters enzymatic activity and recapitulates resistance phenotypes.
The WRN gene exhibits synthetic lethal dependency in multiple MSI-H solid tumors, including colorectal cancer, gastric adenocarcinoma, and endometrial cancer, making it a promising target for precision oncology. In addition, WRN loss or inhibition significantly increases the sensitivity of MSI-H tumors to DNA damage response agents, such as PARP inhibitors, providing a rationale for combination therapy strategies.
Current Landscape of WRN Inhibitors in Development
- HRO761 (Novartis): The first non-covalent WRN inhibitor in Phase I clinical trials (NCT05838768), targeting MSI-H colorectal cancer and other MSI solid tumors.
- NTX-452 (Nimbus Therapeutics): A novel non-covalent WRN inhibitor that demonstrates strong synthetic lethality in preclinical models, with clinical trials planned to initiate in the first half of 2025.
- VVD-133214: A covalent allosteric WRN inhibitor discovered through chemical proteomics, which has advanced to the clinical candidate stage.
- RO7589831: A WRN inhibitor clinical study supported by the U.S. NCI, focusing on multiple MSI-H tumor types.
The HCT116-WRN-KI cell line precisely models the WRN-dependent synthetic lethal phenotype observed in MSI-H tumors and can be used to:
- Identify WRN-associated resistance mechanisms
- Screen and evaluate novel WRN inhibitors
- Optimize combination strategies of WRN inhibitors with other DNA damage agents
WRN-MutCell Platform Products and Services List
- HCT116-WRN-mut-KI in vitro validation data
HCT116-WRN-mut-KI in vivo validation data
1. HCT116-WT
2. HCT116-WRN-C727A
3. HCT116-WRN-C727A
4. HCT116-WRN-C727S
5. RKO-WT
6. RKO-WRN-C727S
References:
Ferretti S, Hamon J, de Kanter R, Scheufler C, Andraos-Rey R, Barbe S, et al. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers. Nature. 2024.
Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019 Apr;568(7753):551–556.
Morales-Juarez DA, Jackson SP. Clinical prospects of WRN inhibition as a treatment for MSI tumours. NPJ Precision Oncology. 2022;6:85.
